RBC Capital analyst Brian Abrahams weighed in on Celgene (NASDAQ: CELG), noting the IP risk to ozanimod is "overblown.""We believe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE